LeMaitre has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 15.5% to $101.53 ...
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, includ...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade...
LeMaitre’s first quarter was marked by double-digit sales growth and significant margin expansion, yet the market responded negatively, reflecting concerns o...
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...
Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio...
Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio...
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Tuesday after market hours. Here’s what you need to know. LeMaitre beat...
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - spe...
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key measure of inflation at the wholesale level, increased by 0.5% in January, significantly higher than the 0.3% anticipated by economists. More concerning was the core PPI, which excludes volatile food and energy prices, as it surged by 0.8%, far exceeding the expected 0.3% rise. This data suggests that inflation may be more entrenched than previously thought, potentially impacting future interest rate decisions. In response to the news, major market indices, including the S&P 500, Dow Jones, and Nasdaq, all traded sharply lower as investors reassessed the economic outlook.
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT)
jumped 16.8% in the morning session after the company reported strong fourth-quarter 2025 results that surpassed Wall Street's expectations for both revenue and earnings. The medical device provider posted sales of $64.45 million, a 15.7% increase from the same period in the previous year. Earnings per share (EPS) grew significantly to $0.68, up from $0.49 in the prior year's quarter and beating analyst forecasts. The company's profitability also saw a notable lift, with its operating margin expanding to 29.2% from 23.1% a year ago. Looking ahead, LeMaitre offered a bright outlook, providing first-quarter revenue guidance that was ahead of consensus and a full-year 2026 GAAP EPS forecast of $2.91 at the midpoint, which was well above market predictions.
